AOD-9604 was safe across six trials but missed its weight-loss goal

What is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone, residues 176-191, with a tyrosine added to the front for stability, which is why it is also called Tyr-hGH fragment 176-191. It is a true peptide, not a GH secretagogue and not a full-length hormone.

The design logic, going back to work summarized by Wilding in 2004, was straightforward. The GH molecule has separate structural regions responsible for its growth-promoting, IGF-1-raising activity and for its lipolytic, fat-mobilizing activity. Isolating the fragment responsible for lipolysis and discarding the rest should yield a fat-loss compound without GH's effects on blood sugar and tissue growth ^[1].

An Australian company, Metabolic Pharmaceuticals, built an entire obesity drug-development program on that premise and took AOD-9604 through six human trials ^[1]. Vendor copy gets that much right. It leaves out how the program ended. The parent fragment's own record stops at rodents.

Does AOD-9604 work through the beta-3 adrenergic receptor?

No. In beta-3 adrenergic receptor knockout mice, chronic AOD9604 treatment failed to change body weight at all ^[3].

In obese mice, chronic AOD9604 administration reduced body weight and body fat over 14 days, and the effect tracked with increased expression of beta-3 adrenergic receptor RNA in fat tissue, a receptor family known to drive lipolysis ^[3]. The knockout experiment then separated the correlation from the cause. The authors' conclusion was that AOD9604's fat-reducing effect is not directly mediated through the beta-3 receptor, despite the correlation ^[3].

The receptor-pathway claim on vendor sites is therefore not settled science. It is an open mechanistic question, in mice.

What did animal studies of AOD-9604 show?

In obese Zucker rats, oral AOD9604 at 500 mcg/kg/day for 19 days cut body-weight gain by more than half and increased lipolytic activity in adipose tissue, without the insulin-sensitivity impairment seen with intact hGH on clamp testing ^[4].

That rat study is well controlled, and it is the strongest mechanistic support for the clean-fragment hypothesis: in rats, AOD9604 separated lipolysis from insulin effects. A rat clamp study is not a human efficacy trial, and the two answer different questions.

No study characterizes a specific human receptor interaction for AOD9604 in detail. The forum claim that AOD-9604 binds a truncated GH receptor isoform and thereby isolates fat burning is a hypothesis consistent with the animal data, not a demonstrated human pathway.

What did AOD-9604's human trials show?

The pivotal 24-week Phase IIb trial of AOD-9604 did not meet its primary endpoint for weight loss versus placebo ^[2]. That trial enrolled 536 participants and was internally referred to as METAOD006, sometimes called the OPTIONS study. It was designed to confirm an earlier signal at scale.

The earlier signal came from a 12-week trial that showed a statistically significant difference from placebo, about 2.6 kg lost versus 0.8 kg ^[2]. The effect is real, and it is small, over a short window, from an early-phase trial.

Metabolic Pharmaceuticals discontinued obesity development after the pivotal result, in 2007. That sentence is missing from nearly every consumer-facing summary of AOD-9604. The company did not simply move on to other applications: the pivotal human efficacy trial failed, on the primary endpoint, in the indication the fragment hypothesis was built to prove.

Is AOD-9604 safe in humans?

AOD-9604 looked clean on safety across Metabolic Pharmaceuticals' six Phase I through IIb randomized, double-blind, placebo-controlled trials, which totaled 893 participants ^[1].

Pooled safety data across those trials showed no measurable effect on IGF-1, no impairment of glucose tolerance, no anti-drug antibodies detected, and no related serious adverse events ^[1]. For the narrow question of whether AOD-9604 looks dangerous in the short term at studied doses, the answer is no, in a company-run trial population monitored for months rather than years.

What is AOD-9604's evidence grade?

AOD-9604 grades C, moderate. It is not a compound with zero human data, unlike much of the gray-market peptide landscape: it has a real Phase 2 program, sizeable enrollment, and a clean safety signal.

The efficacy data are mixed at best, the pivotal trial went negative, and none of the efficacy results appear in a peer-reviewed primary paper. What is available comes through company disclosures and secondary review citations ^[2]. A compound that failed its own developer's confirmatory trial, and whose efficacy data live only in press releases and review-article summaries, cannot be graded higher than moderate however clean the safety profile looks.

Where do AOD-9604 injection protocols come from?

AOD-9604 injection protocols come from vendor copy, not from the trials. The studies behind the safety signal and the modest early efficacy signal used oral dosing, around 1 mg/day in humans ^[2], and 500 mcg/kg/day in the rat efficacy study ^[4].

The standard forum protocol, 250 to 500 mcg subcutaneous, taken fasted in the morning and again pre-workout, maps onto no dosing regimen in the cited trials. It is copied across vendor sites with a specificity that implies a clinical source it does not have. Identical numbers with identical timing language on every page selling a product indicate shared marketing copy rather than shared clinical data. The wider problem with oral peptide dosing is covered in why peptides can't be swallowed.

AOD-9604 does hold GRAS status as a food ingredient in some jurisdictions. That regulatory fact speaks to food safety, a different bar from the one that matters for use as a fat-loss injectable, and it says nothing about efficacy.

What is still unknown about AOD-9604?

Four questions sit outside what the trials measured:

• Long-term safety. Human safety beyond the studied trial windows is uncharacterized ^[1].
• Route. Whether subcutaneous dosing behaves like the oral dosing used in the human trials is untested.
• Translation. Whether the mouse and rat lipolytic mechanisms generalize to humans in a way that could separate from placebo in a larger or longer trial is unknown.
• Product quality. Purity, sterility, and accurate dosing of gray-market material were not controlled for in any trial and cannot be verified from a vendor page. Reading a peptide COA covers what testing paperwork does and does not establish.

A real drug-development program tested AOD-9604's central hypothesis at scale and the hypothesis lost. The mechanism sold on forums rests on rodent biology and a failed human confirmation trial, presented with far more certainty than either supports.